Relay Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$17.29

−4.09%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:09 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $18.03
Volume: 7,035
Day's high: —
Day's low: —

In brief

Relay Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $3.79B.
Its shares closed at $18.03 on 4 Nov 2026, up 162.8% over the past year.
From India you can buy RLAY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Relay Therapeutics, Inc. (RLAY) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RLAY share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RLAY options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −3.8% (SPY −1.6%, XLV +13.5%). 3 months: −8.4% (SPY −0.4%, XLV +15.5%). 1 year: +162.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RLAY, SPY and XLV · as of 4 Nov 2026
16.0 days to cover short interest
44.0M shares were sold short at the 15 Oct 2026 settlement, 20.1% of the 219.1M shares outstanding; covering them would take 16.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $18.03 was 1.9% below its 50-day average ($18.38) and 19.0% above its 200-day average ($15.15). It has closed above the 200-day for 296 sessions, since 3 Sep 2025. The 50-day average crossed above the 200-day on 12 Sep 2025, 288 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $18.03 on 4 Nov 2026: 15.2% below the 52-week high of $21.27 (19 Aug 2026) and 203.0% above the low of $5.95 (11 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.8%

6 months+39.6%

1 year+162.8%

5 years−50.4%

Newswire

About

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Website

Notable moves

September 9, 2024
+52.40%
April 18, 2023
−36.22%
September 8, 2022
+23.75%

Relay Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$17.29

−4.09%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:09 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $18.03
Volume: 7,035
Day's high: —
Day's low: —

In brief

Relay Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $3.79B.
Its shares closed at $18.03 on 4 Nov 2026, up 162.8% over the past year.
From India you can buy RLAY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Relay Therapeutics, Inc. (RLAY) shares from India?

Do I need the price of a whole RLAY share to invest?

How much can I invest in US stocks in a year?

Can I trade RLAY options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −3.8% (SPY −1.6%, XLV +13.5%). 3 months: −8.4% (SPY −0.4%, XLV +15.5%). 1 year: +162.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RLAY, SPY and XLV · as of 4 Nov 2026
16.0 days to cover short interest
44.0M shares were sold short at the 15 Oct 2026 settlement, 20.1% of the 219.1M shares outstanding; covering them would take 16.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $18.03 was 1.9% below its 50-day average ($18.38) and 19.0% above its 200-day average ($15.15). It has closed above the 200-day for 296 sessions, since 3 Sep 2025. The 50-day average crossed above the 200-day on 12 Sep 2025, 288 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $18.03 on 4 Nov 2026: 15.2% below the 52-week high of $21.27 (19 Aug 2026) and 203.0% above the low of $5.95 (11 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.8%

6 months+39.6%

1 year+162.8%

5 years−50.4%

Newswire

About

Website

Notable moves

September 9, 2024
+52.40%
April 18, 2023
−36.22%
September 8, 2022
+23.75%

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

16.0 days to cover short interest

Below its 50-day average, above its 200-day

79% of the way up its 52-week range

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

16.0 days to cover short interest

Below its 50-day average, above its 200-day

79% of the way up its 52-week range